Link between distal sensory polyneuropathy, insulin-like growth factor-I and bone mineral density in elderly diabetics

Authors

  • Moatassem S. Amer Department of Geriatrics and Gerontology, Ain Shams University, Abbassia, Cairo
  • Tomader T. Abdel Rahman Department of Geriatrics and Gerontology, Ain Shams University, Abbassia, Cairo
  • Nermien N. Adly Department of Geriatrics and Gerontology, Ain Shams University, Abbassia, Cairo
  • Hany I. Hassanin Department of Geriatrics and Gerontology, Ain Shams University, Abbassia, Cairo

Keywords:

Type 2 diabetes mellitus, Bone mineral density, Sensory neuropathy, IGF-1

Abstract

Background: The association between Distal Sensory Polyneuropathy (DSP) and systemic osteopenia was studied before in type 1 Diabetes Mellitus (DM), however, is not all clear, with scanty researches in type 2 DM. In addition, Insulin-like Growth Factor-I (IGF-1) could be the most important mediator of bone growth, and an important neurotrophic factor for peripheral sensory neurons. Therefore, the aim of this study was to study the association between bone mineral density (BMD) and DSP, in elderly patients with type 2 DM, and the link between IGF-1 and both BMD and DSP.

Methods: Eighty eight elderly patients, aged ≥60 years, were involved in this case (43 diabetics with DSP and 17 diabetics without DSP) - control (28 non diabetics) study. BMD and IGF-1 were measured.  

Results: There was no significant difference between cases and controls regarding T score of either lumbar spine or femoral neck or IGF-1 (P = 0.83, 0.96 and 0.17 consecutively). DM without DSP had higher IGF-1 than both DM with DSP& the control group (P = 0.011 and 0.010 consecutively). IGF-1 was a significant predictor of T score of both femoral neck and lumbar spine, only in the control group (P = 0.008 and <0.001 consecutively) (OR=1.44 and 2.4 consecutively) (CI=1.1-1.9 and 1.9-3.1 consecutively). Neither DSP nor IGF-1 was (were) a significant predictor of BMD in diabetics.

Conclusion: There was no association between type 2 DM and BMD. IGF-1 was higher in diabetics without DSP than those with DSP or the control group. IGF-1 was a positive predictor of BMD only in the control group.

 

References

Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry. 2006;77(3):354-8.

Tracy JA, Dyck P JB. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19(1):1-v.

Laviola L, Natalicchio A, Giorgino F. The IGF-I signalling pathway. Current Pharma Design. 2007;13:663-9.

Ishii DN, Glazner GW, Pu SF. Role of insulin-like growth factors in peripheral nerve regeneration. Pharmacol Ther. 1994;62:125-44.

Goldspink G. Loss of muscle strength during aging studied at the gene level. Rejuven Res. 2007;10:397-405.

McCarthy TL, Centrella M, Canalis E. Insulin-like growth factor (IGF) and bone. Connective Tissue Res. 1989;20:277-82.

Mohan S. Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul. 1993;3:67-70.

Forst T, Pfützner A, Kann P, Schehler B, Lobman R, Schäfer H, Andreas J, Bockisch A, Beyer J. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med. 1995;12:874-9.

Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabet Care. 1999;22:827-31.

U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults recommendation statement, 2008. Available at: http://www.uspreventiveservicestaskforce.org/uspstf08/type2/type2rs.htm. Accessed 6 February 2014.

American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabet Care. 2013;36(Suppl 1):S67-74.

Meijer JWG, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the diabetic neuropathy symptom score. Diabet Med. 2002;19:962-5.

Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G et al. The diagnostic criteria for small fiber neuropathy: from symptoms to neuropathology. Brain. 2008;131:1912-25.

Thomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabet. 1997;46(Suppl 2):S54-7.

Manz, P. Minnesota Department of Human Services (DHS) has updated the alternative care (AC), brain injury (BI), community alternatives for disabled individuals (CADI) and elderly waiver (EW) case: mix classification worksheet form 3428B, 2013. Available at: https://edocs.dhs.state.mn.us/lfserver/Public/DHS-3428B-ENG. Accessed 22 October 2013.

Donofrio PD, Albers JW. AAEM minimonograph 34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve. 1990;13:889-903.

Usuki S. Prospective role of β-cell-specific IGF-1 for oxidative stress in the pathogenesis of diabetic neuropathy. J Diabet Metab. 2012;S5:1-6.

Janssen JA, Lamberts SW. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf). 2000;52(1):1-9.

Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol. 1998;82:725-30.

Migdalis IN, Kalogeropoulou K, Kalantzis L, Nounopoulos C, Bouloukos A, Samartzis M. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med. 1995;12(9):823-7.

Premkumar LS, Pabbidi RM. Diabetic Peripheral Neuropathy: Role of Reactive Oxygen and Nitrogen Species. Cell Biochem Biophys. 2013;67(2):373-83.

Guo H, Yang Y, Geng Z, Zhu L, Yuan S, Zhao Y, Gao Y, Fu H. The change of insulin-like growth factor-1 in diabetic patients with neuropathy. Chin Med J (Engl). 1999;112(1):76-9.

Tanaka H, Quarto R, Williams S, Barnes J, Liang CT. In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone. 1994;15:647-53.

Hou P, Sato T, Hofstetter W, Foged NT. Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts. J Bone Mineral Res. 1997;12:534-40.

Jonsson KB, Wiberg K, Ljunghall S, Ljunggren O. Insulin-like growth factor I does not stimulate bone resorption in cultured neonatal mouse calvarial bones. Calcified Tissue Int. 1996;59:366-70.

Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab. 1996;81:3864-70.

Karam JH. Pancreatic hormones and diabetes mellitus. In: Greenspan FS, Strewler GJ, eds. Basic and Clinical Endocrinology. Stamford CT USA: Appleton & Lange; 1997: 601-602.

Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 2001;15:1926-34.

Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocrine Rev. 2008;29:535-59.

Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen K, LeRoith D. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009;44(4):648-55.

Sharifi F, Ahmadimoghadam N, Mousavinasab N. The relationship between type 2 diabetes mellitus and bone density in postmenopausal women. Int J Endocrinol Metab. 2006;4(3):117-22.

Sahin G, Bagis S, Cimen OB, Ozisik S, Guler H, Erdogan C. Lumbar and femoral bone mineral density in type 2 Turkish diabetic patients. Acta Med (Hradec Kralove). 2001;44:141-3.

Ziegler R. Diabetes mellitus and bone metabolism. Horm Metab Res Suppl. 1992;26:90-4.

Chen HL, Deng LL, Li JF. The prevalence of osteoporosis and its associated factors among older men with type 2 diabetes. Int J Endocrinol. 2013;2013:285729.

MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabet. 1995;44:775-82.

Amir G, Rosenmann E, Sherman Y, Greenfeld Z, Ne’eman Z, Cohen AM. Osteoporosis in the Cohen diabetic rat: correlation between histomorphometric changes in bone and microangiopathy. Lab Invest. 2002;82:1399-1405.

Edmonds ME, Clarke MB, Newton S, Barrett J, Watkins PJ. Increased uptake of radiopharmaceutical in diabetic neuropathy. Q J Med. 1985;57:843-55.

Stevens MJ, Edmonds ME, Foster AVM, Douglas SLE, Watkins PJ. Paradoxical blood flow responses in the diabetic neuropathic foot: an assessment of the contribution of vascular denervation and microangiopathy. Diabet Med. 1992;9:49-54.

Purewal TS, Goss DE, Watkins PJ, Edmonds ME. Lower limb venous pressure in diabetic neuropathy. Diabet Care. 1995;18:377-81.

Downloads

Published

2017-01-23

How to Cite

Amer, M. S., Rahman, T. T. A., Adly, N. N., & Hassanin, H. I. (2017). Link between distal sensory polyneuropathy, insulin-like growth factor-I and bone mineral density in elderly diabetics. International Journal of Research in Medical Sciences, 2(2), 409–414. Retrieved from https://www.msjonline.org/index.php/ijrms/article/view/2164

Issue

Section

Original Research Articles